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Background:  Recent  studies  suggest  a possible  causal  role  for smoking  in  schizophrenia  and  psychosis.
Most  studies  have  focused  on  cigarette  smoking,  the most  common  form  of  tobacco  use,  but other  forms
of  tobacco  exist,  including  smokeless  products  such  as  Swedish  snuff  (or  “snus”).
Methods: We  explored  whether  snus  use is  associated  with  schizophrenia  and  non-affective  psychotic
illness  in  a large  Swedish  registry  data  set. The  majority  of participants  were  aged  18  or 19 at  the  time  of
assessment.
Results:  We  observed  a positive  association  between  snus  use and  odds  of schizophrenia  in  all  analyses,
but  the  magnitude  of  the association  was  small  and  the conﬁdence  interval  wide,  consistent  with  no
association  (fully  adjusted  HR  1.03,  95%  0.70–1.54).  A  similar  pattern  was  observed  for  non-affective
psychosis,  but the  magnitude  of the association  was  somewhat  greater  and  the conﬁdence  intervals
narrower,  so that these  analyses  provided  stronger  statistical  evidence  for this  association  (fully  adjusted
HR 1.22,  95%  CI, 1.00–1.48).
Conclusions:  Our  results  therefore  provide  modest  evidence  for  an  association  between  snus  use  and
risk  for non-affective  psychosis.  This  is  consistent  with  emerging  evidence  from  a range  of  studies  and
methodologies  that  tobacco  use  may  be  a risk  factor  for psychotic  illness.  However,  our  results  pro-
vide  some  evidence  against  the  hypothesis  that  it is  the  burnt  products  of  cigarette  smoke  that  are
psychotogenic.
© 2016  The  Authors.  Published  by  Elsevier  Ireland  Ltd.  This  is an open  access  article  under  the  CC  BY
license  (http://creativecommons.org/licenses/by/4.0/).
1. Introduction
Tobacco use prevalence is considerably higher among psychi-
atric patients, including people with schizophrenia, compared with
the general population (de Leon and Diaz, 2005). For the most part,
it has been assumed that this comorbidity reﬂects, at least in part,
self-medication on the part of individuals with schizophrenia, to
remediate either the symptoms of the disease, or the side-effects
of antipsychotic medication. The possibility that the association
may  reﬂect a causal effect of tobacco use on schizophrenia risk
has not received widespread consideration, despite the fact that
tobacco use typically predates the onset of psychotic symptoms.
∗ Corresponding author at: School of Experimental Psychology, University of Bris-
tol,  12a Priory Road, Bristol BS8 1TU, United Kingdom.
E-mail address: marcus.munafo@bristol.ac.uk (M.R. Munafò).
1 These authors jointly supervised this work.
If smoking is indeed a causal risk factor for schizophrenia, then
this has important implications for public health, prevention and
treatment.
A recent genome-wide association study of schizophre-
nia (Schizophrenia-Working-Group-of-the-Psychiatric-Genomics-
Consortium, 2014) identiﬁed a locus in the CHRNA5-A3-B4 gene
cluster on chromosome 15, which has been consistently shown to
be associated with heaviness of smoking (Tobacco-and-Genetics-
Consortium, 2010). One possible explanation for this ﬁnding is
that this signal captures a causal effect of cigarette smoking on
schizophrenia (Gage and Munafo, 2015). There is a precedent for
this pattern of results: the same region was  shown to be associ-
ated with lung cancer risk (Thorgeirsson et al., 2008) but it is likely
that this effect arises entirely via cigarette smoking (Munafo et al.,
2012).
Intriguingly, several other recent studies have been published
which also support a causal role for smoking in schizophrenia and
psychosis (Gurillo et al., 2015; Kendler et al., 2015; McGrath et al.,
http://dx.doi.org/10.1016/j.drugalcdep.2016.04.035
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2015; Wium-Andersen et al., 2015). One study reported a stratiﬁed
analysis which suggests an association of CHRNA5-A3-B4 genotype
with antipsychotic medication prescription (as a proxy of psychotic
illness) in ever smokers but not in never smokers (Wium-Andersen
et al., 2015). Another used Swedish registry data to show that
cigarette smoking predicted subsequent diagnosis of schizophre-
nia, and this association was not substantially altered either by
potential confounders either using standard regression methods or
co-relative analyses, or by the inclusion of a buffer period to account
for the possibility that prodromal symptoms of schizophrenia prior
to a diagnosis might lead to the uptake of smoking (Munafo et al.,
2012).
Most studies to date have focused on cigarette smoking, largely
because this is by far the most common form of tobacco use. How-
ever, other forms of tobacco use exist, such as smokeless forms
including oral preparation such as Swedish snuff (or “snus”). Snus
is a most powder tobacco product, typically sold in prepackaged
pouches and usually placed under the upper lip. In general, snus use
is associated with lower levels of harm than cigarette smoking (Le
Houezec et al., 2011), although the evidence with respect to psychi-
atric outcomes is limited. We  therefore explored whether a similar
pattern of association is seen between snus use and schizophre-
nia and non-affective psychotic illness in a large Swedish registry
data set. There is clear evidence that schizophrenia lies at the end
of a continuum of vulnerability to psychotic-like symptoms and
psychosis. Including non-affective psychosis therefore allowed us
to increase statistical power while still addressing our underlying
question.
2. Methods
2.1. Participants
We  linked nationwide Swedish registers via the unique 10-
digit identiﬁcation number assigned at birth or immigration to all
Swedish residents. The identiﬁcation number was replaced by a
serial number to ensure anonymity. Our database contained the
following sources: the Multi-Generation Register, the Swedish Hos-
pital Discharge Register, the Swedish Prescribed Drug Register, the
Outpatient Care Register, the Primary Health Care Register, the
Swedish Crime Register, the Swedish Suspicion Register, the Mil-
itary Conscription Register, the Population and Housing Censuses,
and the Total Population Register. More information on these data
sources is provided as Supplementary material. Males with valid
snus and smoking assessments, aged 18–25 at the time of con-
scription were eligible for inclusion. During the period sampled,
all Swedish males were required by law to attend two days of
evaluation for conscription. Only individuals with prior disabili-
ties or serious criminal or behavioral disturbances were exempted.
Around 97% of males are included in this sample. End of follow-up
was the last year of information available, which for most registries
was 2010.
2.2. Measures
We  identiﬁed smoking and snus habits in young males
from the Military Conscription Register. Snus use was assessed
as “Yes” or “No”, while smoking was assessed as follows:
(1) “Not smoking”, (2) Light smoking—(Winkleby et al., 2007)
“1–10 cigarettes/day”, or “1 packet of tobacco/week”, (3) Aver-
age smoking—“11–20 cigarettes/day”, or “1–2 packets/week”, and
(4) heavy smoking—“>20 cigarettes/day”, or “>2 packets/week.”
Schizophrenia (SZ) was deﬁned in the Swedish Hospital Discharge
Register by the following ICD 10 codes: F20.0, F20.1, F20.2, F20.3,
F20.5, F20.8, and F20.9. Non-affective psychosis (NAP) was deﬁned
by the ICD 10 code: F2. More information on these codes is provided
as Supplementary material.
Drug abuse (DA) was deﬁned as follows: in the Swedish med-
ical registries by ICD 10 codes: F10-F19, except (F10) or (F17);
in the Suspicion Register by codes 3070, 5010, 5011, and 5012,
that reﬂect crimes related to DA; and in the Crime Register by
references to laws covering narcotics (law 1968:64, paragraph 1,
point 6) and drug-related driving offences (law 1951:649, para-
graph 4, subsection 2 and paragraph 4A, subsection 2). DA was
identiﬁed in individuals (excluding those suffering from cancer) in
the Prescribed Drug Register who  had retrieved (in average) more
than four deﬁned daily doses a day for 12 months from either of
Hypnotics and Sedatives (Anatomical Therapeutic Chemical (ATC)
Classiﬁcation System N05C and N05BA) or Opioids (ATC: N02A).
These levels were set to be beyond what any responsible physician
in Sweden would prescribe for anxiety or pain and would only arise
from someone who is abusing the medications, often through get-
ting multiple prescriptions from different physicians. This method
of drug abuse assessment is validated by the strong correlation in
probability of registration for drug abuse from medical and crime
registries.
Family level socioeconomic status was assessed by low parental
education, deﬁned as elementary school only to index low educa-
tional attainment. Neighborhood level socioeconomic status was
assessed by a composite measure of neighbourhood deprivation
(Winkleby et al., 2007), which has been validated in prior stud-
ies (Chaikiat et al., 2012; Winkleby et al., 2007). In the year of
conscription, this measure was classiﬁed into low, mid  and high.
This approach avoids problems associated with classifying socioe-
conomic status at the individual level, which may be impacted by
current and recent behavior (e.g. drug use).
2.3. Statistical analysis
We  investigated the association between snus and time to
diagnosis in males not diagnosed with non-affective psychosis
(including schizophrenia) before conscription with Cox propor-
tional hazard methods, censoring at death or end of follow-up.
The association between smoking and schizophrenia/non-affective
psychosis is known and we therefore included the smoking × snus
interaction in the model.
In addition to unadjusted analyses we  adjusted for socioeco-
nomic status, assessed as parental education at the individual level
and neighbourhood deprivation, and DA before SZ/NAP onset. To
facilitate interpretation, we  present the snus associations sepa-
rately by smoking category. Statistical analyses were performed
using SAS 9.3 (18).
3. Results
3.1. Characteristics of participants
Of the 227,117 individuals fulﬁlling the inclusion criteria, 60,804
(26.8%) reported being snus users. The vast majority of participants
(N = 223,412, 98.4%) were aged 18 or 19 at the time of assessment.
A full description of the characteristics of participants, including
snus users and non-users, is provided in Table 1.
3.2. Association of snus use with schizophrenia and non-affective
psychosis
There was a positive association between snus use and odds
of schizophrenia in all analyses, but the magnitude of the associa-
tions were small and the conﬁdence intervals wide (unadjusted HR
1.13, 95% CI 0.77–1.67; partially adjusted HR 1.14, 955CI 0.77–1.68;
fully adjusted HR 1.03, 95% 0.70–1.54) (Table 2). However, the small
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Table  1
Characteristics of participants.
All N = 227,117 Not using snus N = 166,313 Using snus N = 60,804
Birth year, mean (SD) 1986.4 (2.0) 1986.5 (2.0) 1986.2 (1.9)
Age  at conscript, mean (SD) 18.2 (0.5) 18.2 (0.5) 18.3 (0.5)
Age  at end of follow up, mean (SD) 26.1 (2.1) 26.1 (2.1) 26.3 (2.0)
With  non-affective psychosis (%) 473 (0.21%) 316 (0.19%) 157 (0.26%)
With  schizophrenia (%) 120 (0.05%) 84 (0.05%) 36 (0.06%)
Low  neighbourhood deprivation (%) 57,125 (25.2%) 43,195 (26.0%) 13,930 (22.9%)
Medium neighbourhood deprivation (%) 137,047 (60.3%) 98,885 (59.5%) 38,162 (62.8%)
High  neighbourhood deprivation (%) 31,941 (14.1%) 23,513 (14.1%) 8428 (13.9%)
Low  parental education (%) 24,456 (10.8%) 16,840 (10.1%) 7616 (12.5%)
Drug  abuse (before diagnosis) (%) 15,206 (6.7%) 8496 (5.11%) 6710 (11.0%)
Table 2
Association of snus use with schizophrenia/non-affective psychosis, by smoking
status.
Unadjusted Partially adjusteda Fully adjustedb
Schizophrenia
Combined 1.13 (0.77, 1.67) 1.14 (0.77, 1.68) 1.03 (0.70, 1.54)
Non-smoker 1.29 (0.81, 2.08) 1.30 (0.81, 2.08) 1.23 (0.77, 1.98)
Light smoker 0.38 (0.15, 0.97) 1.39 (0.15, 1.01) 0.42 (0.16, 1.07)
Moderate smoker 0.67 (0.17, 2.57) 0.69 (0.18, 2.70) 0.75 (0.19, 2.92)
Heavy smoker 1.22 (0.25, 6.04) 1.26 (0.26, 6.22) 1.43 (0.29, 2.08)
Non-affective psychosis
Combined 1.33 (1.10, 1.61) 1.33 (1.09, 1.61) 1.22 (1.00, 1.48)
Non-smoker 1.44 (1.14, 1.82) 1.45 (1.15, 1.83) 1.38 (1.09, 1.75)
Light smoker 0.65 (0.43, 0.99) 0.66 (0.43, 1.00) 0.69 (0.45, 1.05)
Moderate smoker 0.87 (0.45, 1.67) 0.90 (0.47, 1.74) 0.97 (0.50, 1.87)
Heavy smoker 0.54 (0.17, 1.75) 0.56 (0.17, 1.81) 0.63 (0.19, 2.06)
Values represent hazard ratios (95% conﬁdence interval). Light smoking is deﬁned
as  1–10 cigarettes/day, or 1 packet of tobacco/week, moderate smoking as 11–20
cigarettes/day, or 1–2 packets/week, and heavy smoking as >20 cigarettes/day, or
>2  packets/week. Analyses in combined sample are adjusted for smoking status.
a Additionally adjusted for neighbourhood deprivation, parental education.
b Additionally adjusted for drug abuse prior to diagnosis.
number of schizophrenia cases in these analyses meant that statis-
tical power was low.
A similar pattern was observed for non-affective psychosis
(including schizophrenia), but the magnitude of the association
was somewhat greater and the conﬁdence intervals narrower.
These analyses provided statistical evidence that this associa-
tion was unlikely due to chance effects (unadjusted HR 1.33, 95%
CI 1.10–1.61; partially adjusted HR 1.33, 95% CI 1.09–1.61; fully
adjusted HR 1.22, 95% CI, 1.00–1.48) (Table 2).
3.3. Association by smoking status
We  examined the relationship between snus use and risk for
schizophrenia and non-affective psychosis separately by cigarette
smoking status (Table 2). Evidence for an association was only reli-
ably seen in non-smokers where, for non-affective psychosis, the
HR was approximately 1.4 and changed little with adjustment.
4. Discussion
Our results provide modest evidence for an association between
snus use and risk for non-affective psychosis. Although a broadly
similar pattern of results was observed for snus use and schizophre-
nia, our analysis was underpowered for this outcome, making it
difﬁcult to draw any conclusions with conﬁdence. When we consid-
ered snus use separately in non-smokers and smokers we observed
similar evidence for an association with non-affective psychosis but
only in non-smokers, and not in smokers. While the magnitude of
the associations we observed was modest, for a common exposure
such as tobacco use the population level impact of any causal effect
will nevertheless be substantial.
It is notable that the association between snus use and risk for
non-affective psychosis was  only observed in non-smokers. This
may  be because, among smokers who  also use snus, cigarettes rep-
resent the major source of tobacco exposure. However, we also
observed evidence among smokers of a modest negative correla-
tion between snus use and cigarette use. This may reﬂect partial
nicotine substitution among dual users, where snus use leads to a
corresponding reduction in cigarette smoking, given that tobacco
users typically titrate intake to achieve the desired nicotine level.
Dissecting the relative contribution of snus and cigarette exposure
among dual users is therefore likely to be complex. Taken together,
these results provide some evidence against the hypothesis that it
is the burnt products of cigarette smoke that are psychotogenic.
There are some limitations that should be considered when
interpreting these results. First, despite the relatively large sample
size, our study was  most likely underpowered to detect mod-
est associations between snus use and a rare outcome such as
schizophrenia. However, the overall pattern of results was  broadly
similar for both outcomes, which increases conﬁdence somewhat
in these ﬁndings. Second, as with any observational analysis, we
cannot fully exclude the possibility that residual confounding or
reverse causality may  account for the associations we observed.
However, the current results are consistent with emerging evi-
dence from a range of studies and methodologies that tobacco use
may  be a risk factor for psychotic illness. Third, the sample included
only conscripted males, and was predominantly of European ances-
try, so that the ﬁndings are not necessarily generalizable to other
populations. It is worth noting that attending the conscript evalu-
ation is mandatory for males in Sweden, so that the sample should
be representative of the male Swedish population over the period
sampled.
In conclusion, our data provide some evidence that snus use
is associated with the subsequent development of non-affective
psychosis. The evidence for an association with schizophrenia
is weaker, but broadly consistent. Given growing evidence that
tobacco use may  play a role in the aetiology of psychotic illness,
these results are potentially important in that they suggest that
any causal agent is present in unburned tobacco. One candidate
agent is nicotine, which inﬂuences dopaminergic signaling in sev-
eral brain regions (Subramaniyan and Dani, 2015). However, there
are other constituents of tobacco that are also plausible candidates,
such as monoamine oxidase inhibitors (Hogg, 2015). If tobacco use
is in fact a risk factor for psychotic illness, it will be important to
identify the constituents responsible, in particular given growing
interest in the use of nicotine-containing products (e.g., elec-
tronic cigarettes) for harm reduction, including among psychiatric
patients.
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